Noida-based Jubilant Ingrevia Ltd, part of the Jubilant Bhartia Group, is beginning to see returns from its nearly ₹2,000-crore investment push into specialty chemicals, outsourced manufacturing and nutrition ingredients, as the company accelerates its shift away from cyclical commodity chemicals toward higher-margin global specialty businesses.
The company said it has deployed over ₹2,000 crore in new plants, technology upgrades and specialty manufacturing capabilities over the past two years, including agro-CDMO facilities, semiconductor chemistry infrastructure and multi-purpose specialty plants.
Management said the investment cycle will continue into FY27 with expansion of the multi-purpose plant at Gajraula, scale-up of semiconductor R&D infrastructure and continued investments in advanced technologies such as flow chemistry and cryogenic systems.
Commenting on the company’s performance, Deepak Jain, Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited said: “Over the past year, we have made strong progress across all strategic pillars, building long term growth while managing global challenges effectively. Despite West Asia disruptions impacting supply and prices, our diversified sourcing and agility ensured minimal disruption with effective cost pass through. Strong customer engagement and timely renegotiations have strengthened resilience, reflected in improved performance in Q4.”
The company reported a 12 per cent year-on-year rise in consolidated revenue to ₹1,179 crore in Q4FY26 from ₹1,051 crore a year earlier, while EBITDA grew 11 per cent to ₹172 crore from ₹155 crore. Net profit rose 17 per cent to ₹86 crore during the quarter. For the full year FY26, revenue increased 5 per cent to ₹4,388 crore, EBITDA rose 9 per cent to ₹607 crore, and profit after tax climbed 11 per cent to ₹278 crore.
“We are pleased to report a healthy performance in Q4 and FY26. Our revenue grew 12 per cent YoY and EBITDA increased 11 per cent YoY, reflecting our strong execution,” Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia said in the investor presentation.
Specialty Businesses Lead Growth
The sharpest momentum came from Specialty Chemicals and Nutrition, while the company’s traditional chemical intermediates business continued to remain under pressure.
Specialty Chemicals, which includes pyridine derivatives, fine chemicals and CDMO operations, reported a 6 per cent rise in Q4 revenue to ₹516 crore, while EBITDA increased 8 per cent to ₹139 crore with margins holding at 27 per cent. Full-year EBITDA from the segment rose 21 per cent to ₹510 crore in FY26 from ₹422 crore in FY25.
CDMO (Custom Development and Manufacturing Organisation) refers to outsourced manufacturing partnerships where global innovators contract chemical companies such as Jubilant Ingrevia to develop and produce specialised molecules using complex chemistry processes.
During FY26, the company commissioned its agro-CDMO facility and started shipments to a global agro innovator, while also expanding semiconductor chemistry capabilities and customer pipelines in pharmaceuticals and personal care.
Nutrition, Human Premixes Gain Traction
Nutrition & Health Solutions emerged as the fastest-growing business in volume terms, with Q4 revenue rising 21 per cent year-on-year to ₹230 crore, driven by Vitamin B3, cosmetic-grade niacinamide and premixes.
The company also expanded into human nutrition premixes through the Remidex Pharma acquisition as it moves deeper into higher-value formulation-led products.
Commodity Chemicals Continue to Lag
In contrast, the Chemical Intermediates business reported a cyclical recovery in Q4, with EBITDA rising to ₹22 crore from ₹10 crore a year earlier, aided by higher realisations linked to West Asia supply disruptions. However, full-year EBITDA for the segment still declined 32 per cent to ₹73 crore.
Management said FY27 growth would be led by Specialty Chemicals and Nutrition, with the company expecting sequential growth in revenue and EBITDA starting Q1FY27.